As Russian scientists boast about the high efficacy and low price of their pioneering Sputnik V vaccine, the race for a Covid-19 cure in other countries goes on. RT’s Boom Bust looks into the issue.

As Pfizer, AstraZeneca and Moderna revealed their vaccines, Russia announced plans to produce one billion doses of Sputnik V and provide it at a lower cost than the competition.

The RDIF, the Russian sovereign wealth fund, said the cost one dose of the vaccine for the international markets will be less than $10, which is less than half the price of foreign vaccines with similar efficacy rates.

Also on rt.com

© Frank Hoemann / Sven Simon via Global Look Press
Puzzling higher AstraZeneca vaccine efficacy for smaller dosage explained: It was reportedly tested on people only under 56

In the meantime, Hungary became the first European country to announce plans to begin testing Russia’s Sputnik V.

“Last week, 10 doses of this vaccine arrived in Hungary,” said the country’s foreign minister, Peter Szijjarto.

“This shipment arrived, together with the necessary documentation, for the Hungarian authorities to carry out tests which will help our scientists to decide whether this vaccine is safe, effective, recommended for the Hungarian people or not.”

Shortly after the announcement, the European Commission took issue with Hungary’s Sputnik V trials, raising concerns that bypassing EU regulators could affect public confidence.

For more stories on economy & finance visit RT’s business section

Translate »
Legal Notice: Views expressed in articles published in www.ebusinessbrief.com are those of the authors and www.ebusinessbrief.com or its owners take no responsibility regarding the same. Advertisements in www.ebusinessbrief.com are published for information of the subscribers. www.ebusinessbrief.com does not authenticate, endorse or guarantee any of the products or services or claims made by the Advertisers. Readers are advised to themselves verify the details. No part of this publication may be reproduced by any means without prior written permission from the Editor. Permission is normally granted wherever sufficient acknowledgement is given to www.ebusinessbrief.com.